Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: A review of the literature

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 7, 2010, Pages 1167-1181

  Mancini, Michele ^a   Perna, Giampaolo ^b   Rossi, Andrea ^a   Petralia, Antonino ^c  

^a Eli Lilly Italia   (Italy)

^b San Benedetto Hospital   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Duloxetine; Generalized anxiety disorder; Major depressive disorder; Obsessive compulsive disorder; Panic disorder; Post traumatic stress disorder; Social anxiety disorder

Indexed keywords

ANTACID AGENT; CIMETIDINE; CIPROFLOXACIN; DULOXETINE; ENOXACIN; ESCITALOPRAM; FAMOTIDINE; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; PAROXETINE; PLACEBO; QUINIDINE; TEMAZEPAM; VENLAFAXINE; WARFARIN;

AGING; ANOREXIA; ANXIETY DISORDER; CARDIOVASCULAR EFFECT; CLIMACTERIUM; CLINICAL TRIAL; COMORBIDITY; DATA BASE; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; FATIGUE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LIVER FUNCTION; MAJOR DEPRESSION; MEDLINE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PANIC; PLASMA CONCENTRATION-TIME CURVE; POSTTRAUMATIC STRESS DISORDER; PREDICTOR VARIABLE; PREGNANCY; QUALITY OF LIFE; RATING SCALE; RELAPSE; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; QUALITY OF LIFE; THIOPHENES;

EID: 77951292575     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003747441     Document Type: Review

References (87)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders text revision: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000
2. Stein MB, Roy-Byrne PP, Craske MG, et al. Functional impact and health utility if anxiety disorders in primary care outpatients. Med Care 2005;43:1164-1170
3. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627 (Pubitemid 40973437)
4. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005;15:445-452 (Pubitemid 40943548)
5. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005;66:22-29
6. McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 2003;106:127-133
7. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
8. Feske U, Frank E, Mallinger AG, et al. Anxiety as a correlate of response to acute treatment of bipolar I disorder. Am J Psychiatry 2000;157:956-962 (Pubitemid 30412347)
9. Coryell W, Endicott J, Andreasen NC, et al. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988;145:293-300 (Pubitemid 18078307)
10. Hettema JM, Kuhn JW, Prescott CA, Kendler KS. The impact of generalized anxiety disorder and stressful life events on risk for major depressive episodes. Psychol Med 2006;36:789-795 (Pubitemid 43744772)
11. Bair MJ, Wu J, Damush TM, et al. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med 2008;70:890-897
12. Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009;301:2099-2110
13. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005;66:22-29
14. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry 2002;63:382-383
15. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebocontrolled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399 (Pubitemid 38944137)
16. Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009;43:512-518
17. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993;8:23-33 (Pubitemid 23011155)
18. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003;31:1142-1150 (Pubitemid 37048286)
19. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880
20. Gupta S, Nihalani N. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry 2007;19:125-132 (Pubitemid 47035939)
21. Bymaster FP, Beedle EE, Findlay J, et al. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett 2003;13:4477-4480 (Pubitemid 37490840)
22. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004;57:54-61 (Pubitemid 38067950)
23. Skinner MH, Skerjanec A, Seger M, et al. The effect of food and bedtime administration on duloxetine pharmacokinetics [abstract no. PII-59]. Clin Pharmacol Ther 2000;67:129
24. Whitmyer VG, Dunner DL, Kornstein SG, et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007;68:1921-1930
25. Eli Lilly and Company. Cymbalta- (duloxetine hydrochloride) delayed-release capsules for oral use: Highlights of US prescribing information [online]. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/ 2009/ 021427s029lbl.pdf [Last accessed 8 February 2010]
26. Wells KA, Losin WG. In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding. Clin Ther 2008;30:1300-1308
27. Cymbalta 30 mg hard gastro-resistant capsules, Cymbalta 60 mg hard gastro-resistant capsules, Summary of Product Characteristics, 2009. Available from: http://emc.medicines.org.uk/ medicine/15694/SPC/Cymbalta+30mg +hard+gastro-resistant+capsules, +Cymbalta+60mg+hard+ gastro-resistant+capsules/ #INTERACTIONS#ixzz0JTKT47Xj&D [Last accessed 1 September 2009]
28. Wrase J, Reimold M, Puls I, et al. Serotonergic dysfunction: brain imaging and behavioral correlates. Cogn Affect Behav Neurosci 2006;6:53-61 (Pubitemid 44237733)
29. Schreiber R, Melon C, De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berl) 1998;135:383-391 (Pubitemid 28254845)
30. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000;12:2-19
31. Feldman S, Weidenfeld J. The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. Brain Res Bull 1998;45:389-393 (Pubitemid 28144617)
32. Goddard AW, Ball SG, Martinez J, et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 2009. [Epub ahead of print]
33. Silverstone PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry 2004;65:19-28
34. Troelsen KB, Nielsen EØ, Mirza NR. Chronic treatment with duloxetine is necessary for anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl) 2005;181:741-750 (Pubitemid 41400760)
35. Müller N, Schennach R, Riedel M, M€oller HJ. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother 2008;8:527-536 (Pubitemid 351551006)
36. Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005;21:170-177 (Pubitemid 41170386)
37. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-676
38. Perahia DG, Maina G, Thase ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:706-716
39. Nelson JC. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety 2010;27:12-18
40. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2003;18:53-61 (Pubitemid 37175581)
41. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315 (Pubitemid 34456358)
42. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390 (Pubitemid 35254112)
43. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231 (Pubitemid 34407082)
44. Fava M, Martinez JM, Greist J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry 2007;19:187-195 (Pubitemid 47345874)
45. Joffe H, Soares CN, Petrillo LF, et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007;68:943-950 (Pubitemid 47015497)
46. Kornstein SG, Russell JM, Spann ME, et al. Duloxetine in the treatment of generalized anxiety disorder. Expert Rev Neurother 2009;9:155-165
47. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007;9:100-107 (Pubitemid 46607463)
48. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008;25:182-189 (Pubitemid 351499896)
49. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167-174 (Pubitemid 46559873)
50. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009;39:267-276
51. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebocontrolled trial. Eur Neuropsychopharmacol 2008;18:673-681
52. Perahia DG, Pritchett YL, Desaiah D, et al. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-317 (Pubitemid 44498273)
53. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909 (Pubitemid 46972905)
54. Crippa JA, Filho AS, Freitas MC, Zuardi AW. Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol 2007;27(3):310 (Pubitemid 46763320)
55. Choy Y, Fyer AJ, Lipsitz J. New and recent drugs for anxiety disorders. Prim Psychiatry 2007;15:50-56
56. Nakatani E, Nakagawa A, Nakao T, et al. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder -- effectiveness of behavior therapy and fluvoxamine. Psychother Psychosom 2005;74:269-276 (Pubitemid 41160197)
57. Randhawa RS. A review of the pharmacotheraphy of obsessive-compulsive disorder and schizophrenia: the case of Sam. Cogn Behav Pract 2005;12:395-402
58. Dell'Osso B, Mundo E, Marazziti D, Altamura AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol 2008;22:210-213 (Pubitemid 351322866)
59. Vieweg WV, Julius DA, Fernandez A, et al. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. Am J Med 2006;119:383-390
60. Deneys ML, Ahearn EP. Exacerbation of PTSD symptoms with use of duloxetine. J Clin Psychiatry 2006;67:496-497
61. Hanretta AT, Malek-Ahmadi P. Combined use of ECT with duloxetine and olanzapine: a case report. J ECT 2006;22:139-141 (Pubitemid 44491115)
62. Simon NM, Kaufman RE, Hoge EA, et al. Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther 2009;15:19-23
63. Crippa JA, Zuardi AW. Duloxetine in the treatment of panic disorder. Int J Neuropsychopharmacol 2006;9:633-634
64. Endicott J, Russell JM, Raskin J, et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 2007;68:518-524 (Pubitemid 46663033)
65. Cramer V, Torgersen S, Kringlen E. Quality of life and anxiety disorders: a population study. J Nerv Ment Dis 2005;193:196-202 (Pubitemid 40354844)
66. Stein MB, Roy-Byrne PP, Craske MG, et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005;43:1164-1170
67. Pollack MH, Endicott J, Liebowitz M, et al. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 2008;42:1042-1049
68. Sheehan DV, Meyers AL, Prakash A, et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin 2008;24:2457-2466
69. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005;11:1475-1493
70. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004;26:1446-1455 (Pubitemid 39582713)
71. Davidson J, Allgulander C, Pollack MH, et al. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 2008;23:519-526
72. Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-455 (Pubitemid 46740340)
73. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin psychopharmacol 1988;8:323-330
74. Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006;8:269-278
75. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001;62(Suppl 3):22-34
76. Clayton AH, Balon R. The impact of mental illness and psychotropic medications on sexual functioning: the evidence and management. J Sex Med 2009;6:1200-1211
77. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-692
78. Clayton A, Kornstein S, Prakash A, et al. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4:917-929 (Pubitemid 47082256)
79. Wernicke J, Pangallo B, Wang F, et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf 2008a;3:132-142
80. Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat 2009;5:23-31
81. Menchetti M, Gozzi BF, Saracino MA, et al. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry 2009;10:385-389
82. Zhu B, Zhao Z, Ye W, et al. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J Nerv Ment Dis 2009;197:136-139
83. Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009;23:103-120
84. Barkin RL, Barkin S. The role of velafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005;12:431-438 (Pubitemid 41445141)
85. Harmer CJ, Hill SA, Taylor MJ, et al. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry 2003;160:990-992
86. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, et al. Effects of selective serotonin reuptake and dual serotonergic- noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatry Res 2009;43:855-863
87. Russell JM, Weisberg R, Fava M, et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008;25:E1-11